Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences
More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive opioid withdrawal supported by a rotation to buprenorphine and/or tramadol. The aim of this research is to analyse the long-term effectiveness of opioid deprescription taki...
Saved in:
Main Authors: | Muriel Javier, Escorial Mónica, Margarit César, Barrachina Jordi, Carvajal Cristian, Morales Domingo, Peiró Ana M. |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2023-06-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2023-0018 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024-12-01) -
Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting: An observational study
by: Barrachina Jordi, et al.
Published: (2022-12-01) -
Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation
by: N. B. Zakharzhevskaya, et al.
Published: (2015-12-01) -
Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients
by: Ghada S. Rasool, et al.
Published: (2024-01-01) -
Association between different modalities of opioid use disorder-related care delivery and opioid use disorder-related patient outcomes: A retrospective cohort study
by: Nahiyan Bin Noor, et al.
Published: (2025-06-01)